MCID: VLV010
MIFTS: 45

Vulvovaginitis

Categories: Reproductive diseases

Aliases & Classifications for Vulvovaginitis

MalaCards integrated aliases for Vulvovaginitis:

Name: Vulvovaginitis 12 77 56 45 15 17 74
Vulvo-Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2273
MeSH 45 D014848
NCIt 51 C35131
SNOMED-CT 69 53277000
ICD10 34 N76.0
UMLS 74 C0042998

Summaries for Vulvovaginitis

Disease Ontology : 12 A female reproductive system disease that is characterized by inflammation of the vagina and vulva.

MalaCards based summary : Vulvovaginitis, also known as vulvo-vaginitis, is related to cervicitis and behcet syndrome. An important gene associated with Vulvovaginitis is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Clindamycin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and colon.

Wikipedia : 77 Vaginitis, also known as vulvovaginitis, is inflammation of the vagina and vulva. Symptoms may include... more...

Related Diseases for Vulvovaginitis

Diseases related to Vulvovaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Related Disease Score Top Affiliating Genes
1 cervicitis 30.3 CXCL8 HSPD1
2 behcet syndrome 30.0 CXCL8 HSPD1 IL10
3 allergic rhinitis 30.0 CCL11 CXCL8 IL10
4 allergic contact dermatitis 29.8 CXCL8 IL10
5 contact dermatitis 29.8 CXCL8 IL10
6 chlamydia 29.8 CXCL8 HSPD1 IL10
7 toxic shock syndrome 29.7 CXCL8 IL10
8 oral lichen planus 29.6 CCL5 HSPD1
9 peritonitis 29.6 CXCL8 IL10
10 bacterial infectious disease 29.5 CXCL8 HSPD1 IL10
11 intestinal disease 29.5 CXCL8 IL10
12 human immunodeficiency virus infectious disease 29.5 CCL5 IL10
13 skin disease 29.5 CCL11 CXCL8 IL10
14 allergic hypersensitivity disease 29.3 CCL11 CCL5 IL10
15 rhinitis 29.3 CCL11 CCL5 CXCL8
16 human immunodeficiency virus type 1 29.1 CCL11 CCL5 IL10
17 vulvovaginal candidiasis 12.7
18 vulvovaginal gingival syndrome 12.3
19 vulvovaginal rhabdomyosarcoma 12.2
20 vulvovaginitis, allergic seminal 12.1
21 vaginitis 11.6
22 vulvitis 11.4
23 vulvar vestibulitis syndrome 11.4
24 vulvar disease 11.3
25 candidiasis 11.1
26 lichen planus 10.6
27 bacterial vaginosis 10.4
28 malignant skin fibrous histiocytoma 10.3
29 vaginal cancer 10.3
30 candida glabrata 10.3
31 mycobacterium fortuitum 10.3 CXCL8 HSPD1
32 ulceration of vulva 10.2
33 papillary conjunctivitis 10.2 CCL11 CXCL8
34 conjunctivitis 10.2 CCL11 CXCL8
35 giant papillary conjunctivitis 10.2 CCL11 CXCL8
36 keratoconjunctivitis 10.2 CCL11 CXCL8
37 trichomoniasis 10.2
38 oral candidiasis 10.2
39 allergic conjunctivitis 10.2 CCL11 CXCL8
40 carrion's disease 10.2 CCL11 HSPD1
41 tungiasis 10.2 CXCL8 IL10
42 acute transverse myelitis 10.2 CXCL8 IL10
43 transverse myelitis 10.2 CXCL8 IL10
44 pouchitis 10.2 CXCL8 IL10
45 neurosyphilis 10.1 CXCL8 IL10
46 necatoriasis 10.1 CXCL8 IL10
47 sexual disorder 10.1
48 funisitis 10.1 CXCL8 IL10
49 clonorchiasis 10.1 CXCL8 IL10
50 thrombosis 10.1

Graphical network of the top 20 diseases related to Vulvovaginitis:



Diseases related to Vulvovaginitis

Symptoms & Phenotypes for Vulvovaginitis

Drugs & Therapeutics for Vulvovaginitis

Drugs for Vulvovaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 18323-44-9 29029
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 23593-75-1 2812
4
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Terconazole Approved Phase 4,Phase 3,Not Applicable 67915-31-5 441383
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
9 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antibiotics, Antitubercular Phase 4,Not Applicable
17 Antitubercular Agents Phase 4
18 Clindamycin palmitate Phase 4,Phase 3,Not Applicable
19 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Clindamycin phosphate Phase 4,Phase 3,Not Applicable
21 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Infective Agents, Local Phase 4,Phase 3
25
Butoconazole Approved Phase 3,Not Applicable 64872-76-0, 64872-77-1 47472
26
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
27
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 5280965 14956
28
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
29 Antiprotozoal Agents Phase 3,Phase 2
30 Antiparasitic Agents Phase 3,Phase 2
31 Liposomal amphotericin B Phase 3,Phase 2
32
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
33 Albaconazole Investigational Phase 2 187949-02-6
34 Rezafungin Phase 2
35 Immunologic Factors Phase 1, Phase 2
36 Gastrointestinal Agents Phase 1, Phase 2
37 Antacids Phase 1, Phase 2
38 Adjuvants, Immunologic Phase 1, Phase 2
39 Anti-Ulcer Agents Phase 1, Phase 2
40 Vaccines Phase 1, Phase 2
41 Pharmaceutical Solutions Phase 2
42 Acidophilus Phase 1,Not Applicable,Early Phase 1
43
Iron Approved, Experimental Not Applicable 7439-89-6, 15438-31-0 27284 23925
44
Itraconazole Approved, Investigational Not Applicable 84625-61-6 55283
45
Metronidazole Approved ,Not Applicable 443-48-1 4173
46 Micronutrients Not Applicable
47 Nutrients Not Applicable
48 Trace Elements Not Applicable
49
Hydroxyitraconazole Not Applicable
50 Bifidobacterium Not Applicable

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
2 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
3 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
4 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
5 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
6 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
7 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
8 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
9 ProF-001_Phase IIa Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
10 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
11 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
12 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
13 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
14 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
15 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
16 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03734991 Phase 3 Ibrexafungerp;Placebo
17 A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
18 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03562156 Phase 3 VT-1161;Placebo
19 A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Recruiting NCT03561701 Phase 3 VT-1161;Placebo
20 Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis Not yet recruiting NCT03473418 Phase 3 Ketoconazole;Terconazole
21 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
22 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
23 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
24 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
25 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
26 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
27 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
28 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
29 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161;Fluconazole
30 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
31 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
32 Patients With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
33 Efficacy Vulvovaginitis Candida Terminated NCT00199264 Phase 2 Albaconazole oral solution
34 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
35 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
36 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
37 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
38 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046 Not Applicable
39 Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy Completed NCT01375439 Not Applicable
40 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Not Applicable Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
41 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 Not Applicable itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
42 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Not Applicable Terconazole Vaginal Suppository;Terazol Vaginal Suppository
43 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
44 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
45 Women's Improvement of Sexual Health (WISH) Demonstration Project Completed NCT03045809
46 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
47 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
48 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis Recruiting NCT03762083 Not Applicable
49 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis Recruiting NCT03761628 Not Applicable
50 Probiotic for Vaginal Candidiasis in Pregnant Women Recruiting NCT03940612 Not Applicable

Search NIH Clinical Center for Vulvovaginitis

Cochrane evidence based reviews: vulvovaginitis

Genetic Tests for Vulvovaginitis

Anatomical Context for Vulvovaginitis

MalaCards organs/tissues related to Vulvovaginitis:

42
Testes, Skin, Colon, T Cells, Lymph Node, Eye

Publications for Vulvovaginitis

Articles related to Vulvovaginitis:

(show top 50) (show all 406)
# Title Authors Year
1
Acceptability, tolerability, and effects on symptoms and signs of vulvovaginitis of a non-soap, herbal-based intimate hygiene solution (Zelesse®). ( 31088247 )
2019
2
Erosive Vulvovaginitis Associated With Borrelia burgdorferi Infection. ( 31043089 )
2019
3
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. ( 30885896 )
2019
4
Health care utilization and costs following amplified versus non-amplified molecular probe testing for symptomatic patients with suspected vulvovaginitis: a US commercial payer population. ( 30863131 )
2019
5
50 Years Ago in The Journal of Pediatrics: Vulvovaginitis in the Premenarcheal Child. ( 30798826 )
2019
6
Chronic vulvovaginitis caused by Candida dubliniensis in an immunologically competent adult female. ( 30170531 )
2019
7
An unusual presentation of pseudocowpox associated with an outbreak of pustular ulcerative vulvovaginitis in a Swedish dairy herd. ( 29153035 )
2018
8
Cyproterone acetate in the treatment of oestrogen hypersensitivity vulvovaginitis. ( 28718897 )
2018
9
Prepubertal vulvovaginitis. ( 29970369 )
2018
10
Efficacy, acceptability and tolerability of Zelesse® for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study. ( 29877120 )
2018
11
Effect of 2-Phenylethanol as Antifungal Agent and Common Antifungals (Amphotericin B, Fluconazole, and Itraconazole) on Candida Species Isolated from Chronic and Recurrent Cases of Candidal Vulvovaginitis. ( 29658789 )
2018
12
Parapoxviral vulvovaginitis in Holstein cows. ( 29429402 )
2018
13
A nested-PCR strategy for molecular diagnosis of mollicutes in uncultured biological samples from cows with vulvovaginitis. ( 29191491 )
2018
14
Vulvovaginitis- presentation of more common problems in pediatric and adolescent gynecology. ( 28927766 )
2018
15
An Update on the Roles of Non-albicansCandida Species in Vulvovaginitis. ( 30384449 )
2018
16
Is multiple-site colonization with Candida spp. related to inadequate response to individualized fluconazole maintenance therapy in women with recurrent Candida vulvovaginitis? ( 30293562 )
2018
17
First report of Vulvovaginitis due to Cryptococcus magnus in Iran. ( 30186991 )
2018
18
Sexual behaviour and extra-genital colonisation in women treated for recurrent Candida vulvo-vaginitis. ( 29998617 )
2018
19
Identification of Candida species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. ( 29707675 )
2017
20
Evaluation of esterase and hemolysin activities of different Candida species isolated from vulvovaginitis cases in Lorestan Province, Iran. ( 29707672 )
2017
21
Molecular identification and antifungal susceptibility profile of Candida species isolated from patients with vulvovaginitis in Tehran, Iran. ( 29387119 )
2017
22
Candida Vulvovaginitis and Vulvodynia: The Mystery Continues. ( 28836889 )
2017
23
Stratum corneum lipid liposome-encapsulated panomycocin: preparation, characterization, and the determination of antimycotic efficacy against Candida spp. isolated from patients with vulvovaginitis in an in vitro human vaginal epithelium tissue model. ( 28831255 )
2017
24
Vulvovaginitis: Find the cause to treat it. ( 28322677 )
2017
25
Comparison of enzymatic activities in different Candida species isolated from women with vulvovaginitis. ( 28236530 )
2017
26
Characterization and identification of microbial communities in bovine necrotic vulvovaginitis. ( 28093107 )
2017
27
Clinical presentation, diagnosis and treatment of vulvovaginitis in girls: a current approach and review of the literature. ( 28083751 )
2017
28
Vulvovaginitis and diabetes. ( 28065975 )
2017
29
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 28025698 )
2017
30
Author's reply to comment on: is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 27988816 )
2017
31
Candida vulvovaginitis: A store with a buttery and a show window. ( 27687503 )
2017
32
Clinical Significance and Characteristic Clinical Differences of Cytolytic Vaginosis in Recurrent Vulvovaginitis. ( 27300413 )
2017
33
Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. ( 29017160 )
2017
34
Haemophilus influenzae vulvovaginitis associated with rhinitis caused by the same clone in a prepubertal girl. ( 28621044 )
2017
35
Streptococcus pyogenes as the cause of vulvovaginitis and balanitis in children. ( 27638252 )
2017
36
Dhatakyadi Varti - An effective local treatment for Upapluta Yonivyapad (vulvovaginitis during pregnancy): A standard controlled randomized clinical trial. ( 29200747 )
2016
37
Clinical Recommendation: Vulvovaginitis. ( 27969009 )
2016
38
The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. ( 27796932 )
2016
39
Phospholipase and proteinase activities of Candida spp. isolates from vulvovaginitis in Iran. ( 27544321 )
2016
40
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). ( 27393491 )
2016
41
Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. ( 27132409 )
2016
42
Clinical and microbiologic characteristics of vulvovaginitis in Korean prepubertal girls, 2009-2014: a single center experience. ( 27004204 )
2016
43
Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. ( 26991298 )
2016
44
Recurrent desquamative vulvovaginitis in a young woman. ( 26266812 )
2016
45
Personal Hygiene and Vulvovaginitis in Prepubertal Children. ( 26187769 )
2016
46
Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. ( 26083330 )
2016
47
Theriogenology Question of the Month. Vulvovaginitis or uterine, cervical, or vaginal neoplasia. ( 26642128 )
2015
48
Streptococcal vulvovaginitis in adults: Not a rare entity. ( 26515866 )
2015
49
Prevalence of vulvovaginitis and relation to physical findings in girls assessed for suspected child sexual abuse. ( 26294142 )
2015
50
The Role of PCR in the Diagnosis of Candida Vulvovaginitis-a New Gold Standard? ( 26003471 )
2015

Variations for Vulvovaginitis

Expression for Vulvovaginitis

Search GEO for disease gene expression data for Vulvovaginitis.

Pathways for Vulvovaginitis

Pathways related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 CCL11 CCL5 CXCL8 IL10
2
Show member pathways
12.99 CCL11 CCL5 CXCL8 IL10
3
Show member pathways
12.93 CCL11 CCL5 CXCL8 IL10
4
Show member pathways
12.5 CCL11 CXCL8 HSPD1 IL10
5
Show member pathways
12.01 CCL11 CCL5 CXCL8
6 11.87 CXCL8 HSPD1 IL10
7
Show member pathways
11.64 CCL11 CCL5 CXCL8
8
Show member pathways
11.64 CCL11 CCL5 CXCL8 IL10
9 11.6 CCL11 CXCL8 IL10
10 11.57 CCL5 CXCL8
11 11.49 CXCL8 IL10
12 11.39 CCL11 IL10
13 11.32 CXCL8 HSPD1
14 11.28 CCL11 CCL5 IL10
15 11.25 CXCL8 IL10
16 11.22 CCL11 CXCL8
17 11.2 CCL11 IL10
18 11.18 HSPD1 IL10
19 11.13 CCL11 CCL5 CXCL8
20 10.89 CCL5 CXCL8
21 10.82 CCL5 CXCL8 IL10
22 10.64 CCL11 CCL5 CXCL8 IL10
23 10.15 CCL11 CCL5 CXCL8 IL10

GO Terms for Vulvovaginitis

Cellular components related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 CCL11 CCL5 CXCL8 HSPD1 IL10

Biological processes related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.71 CCL11 CCL5 CXCL8 IL10
2 chemotaxis GO:0006935 9.69 CCL11 CCL5 CXCL8
3 inflammatory response GO:0006954 9.62 CCL11 CCL5 CXCL8 IL10
4 positive regulation of endothelial cell proliferation GO:0001938 9.61 CCL11 IL10
5 cellular response to tumor necrosis factor GO:0071356 9.61 CCL11 CCL5 CXCL8
6 monocyte chemotaxis GO:0002548 9.59 CCL11 CCL5
7 lymphocyte chemotaxis GO:0048247 9.58 CCL11 CCL5
8 B cell proliferation GO:0042100 9.57 HSPD1 IL10
9 cellular response to fibroblast growth factor stimulus GO:0044344 9.56 CCL5 CXCL8
10 leukocyte chemotaxis GO:0030595 9.55 CXCL8 IL10
11 eosinophil chemotaxis GO:0048245 9.54 CCL11 CCL5
12 neutrophil chemotaxis GO:0030593 9.54 CCL11 CCL5 CXCL8
13 positive regulation of macrophage activation GO:0043032 9.52 HSPD1 IL10
14 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.49 CCL5 CXCL8
15 response to molecule of bacterial origin GO:0002237 9.48 CXCL8 IL10
16 neutrophil activation GO:0042119 9.46 CCL5 CXCL8
17 cellular response to interleukin-1 GO:0071347 9.43 CCL11 CCL5 CXCL8
18 chemokine-mediated signaling pathway GO:0070098 9.33 CCL11 CCL5 CXCL8
19 response to glucocorticoid GO:0051384 9.3 IL10
20 response to activity GO:0014823 9.28 IL10
21 cytokine-mediated signaling pathway GO:0019221 9.26 CCL5 CXCL8 IL10 CCL11
22 immune response GO:0006955 9.02 LST1 IL10 CXCL8 CCL5 CCL11

Molecular functions related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.16 CCL11 CCL5
2 chemokine activity GO:0008009 9.13 CCL11 CCL5 CXCL8
3 cytokine activity GO:0005125 8.92 CCL11 CCL5 CXCL8 IL10

Sources for Vulvovaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....